Extended interval dosing with ocrelizumab in multiple sclerosis.

Frederik NovakHamza Mahmood BajwaKamilla ØstergaardJonas Munksgaard BergJonna Skov MadsenDorte Aalund OlsenInga UrbonaviciuteZsolt IllesMorten Leif StilundJeppe Romme ChristensenStephan BramowFinn SellebjergTobias Sejbaek

Published in: Multiple sclerosis (Houndmills, Basingstoke, England) (2024)

Extending one treatment interval of ocrelizumab on average 9 weeks and up to 78 weeks did not result in clinical, radiological, or biomarker evidence of worsening compared with SID.

Keyphrases

multiple sclerosis

gestational age

replacement therapy

preterm birth